clinical trial · NCT07224672
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
AmyloidosisBelantamab mafodotinCyclophosphamideBortezomibDexamethasone
brief summary
The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .
started
Jun 24, 2026
primary completion
Jan 12, 2033
completion
Jan 12, 2033
last updated
Nov 3, 2026
official title
A Phase 2, Open-label, Randomized, Dose Optimization Study Evaluating the Efficacy and Safety of Belantamab Mafodotin Administered in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain Amyloidosis (ALANIS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol